Akeso

πŸ‡¨πŸ‡³China
Ownership
-
Employees
-
Market Cap
$5B
Website

A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor

Phase 1
Not yet recruiting
Conditions
Interventions
First Posted Date
2023-12-12
Last Posted Date
2023-12-12
Lead Sponsor
Akeso
Target Recruit Count
72
Registration Number
NCT06166472
Locations
πŸ‡¨πŸ‡³

Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China

πŸ‡¨πŸ‡³

Sun Yat-Sen University Cancer Center, Guangzhou, China, Guangzhou, Guangdong, China

πŸ‡¨πŸ‡³

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

and more 4 locations

A Study of AK131 in Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2023-12-12
Last Posted Date
2024-01-17
Lead Sponsor
Akeso
Target Recruit Count
130
Registration Number
NCT06166888
Locations
πŸ‡¨πŸ‡³

Jinming Yu, Jinan, Shandong, China

A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2023-10-23
Last Posted Date
2024-11-25
Lead Sponsor
Akeso
Target Recruit Count
180
Registration Number
NCT06092762
Locations
πŸ‡¨πŸ‡³

The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

πŸ‡¨πŸ‡³

People Hospital of Xingtai, Xingtai, Hebei, China

πŸ‡¨πŸ‡³

The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

and more 23 locations

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2023-10-04
Last Posted Date
2023-10-04
Lead Sponsor
Akeso
Target Recruit Count
350
Registration Number
NCT06066125
Locations
πŸ‡¨πŸ‡³

Dermatology Hospital of China Union Medical University, Nanjing, Jiangsu, China

πŸ‡¨πŸ‡³

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

πŸ‡¨πŸ‡³

The first affiliated hospital of Bengbu Medical College, Bengbu, Anhui, China

and more 31 locations

To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2023-09-29
Last Posted Date
2023-12-15
Lead Sponsor
Akeso
Target Recruit Count
150
Registration Number
NCT06061471
Locations
πŸ‡¨πŸ‡³

Dermatology hospital of Jiangxi province, Nanchang, Jiangxi, China

πŸ‡¨πŸ‡³

Hangzhou First People's hospital, Hangzhou, Zhejiang, China

πŸ‡¨πŸ‡³

The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

and more 8 locations

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2023-09-13
Last Posted Date
2023-09-13
Lead Sponsor
Akeso
Target Recruit Count
416
Registration Number
NCT06035354
Locations
πŸ‡¨πŸ‡³

AkesoBio Investigative Site 2037, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

πŸ‡¨πŸ‡³

AkesoBio Investigative Site 2036, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China

πŸ‡¨πŸ‡³

AkesoBio Investigative Site 2022, Dongguan People's Hospital, Dongguan, Guangdong, China

and more 36 locations

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

First Posted Date
2023-08-14
Last Posted Date
2023-08-14
Lead Sponsor
Akeso
Target Recruit Count
642
Registration Number
NCT05990127
Locations
πŸ‡¨πŸ‡³

The Second Xiangya Hospital, Central South University, Changsha, Hunan, China

πŸ‡¨πŸ‡³

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

πŸ‡¨πŸ‡³

Cancer hospital, Chinese academy of medical sciences and Peking union medical college, Beijing, Beijing, China

and more 59 locations

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

First Posted Date
2023-07-27
Last Posted Date
2023-11-18
Lead Sponsor
Akeso
Target Recruit Count
90
Registration Number
NCT05960955
Locations
πŸ‡¨πŸ‡³

Tianjin Provincial Tumor Hospital, Tianjin, China

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

Phase 1
Not yet recruiting
Conditions
Interventions
First Posted Date
2023-07-19
Last Posted Date
2023-07-19
Lead Sponsor
Akeso
Target Recruit Count
216
Registration Number
NCT05951608

A Phase II Study of AK104 for Recurrent or Metastatic Vulvar Cancer

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2023-07-06
Last Posted Date
2023-07-06
Lead Sponsor
Akeso
Target Recruit Count
20
Registration Number
NCT05932212
Locations
πŸ‡¨πŸ‡³

Sun Yant-Sen Memorial Hospital, Guangzhou, Guangdong, China

πŸ‡¨πŸ‡³

Fujian Cancer Hospital, Fuzhou, Fujian, China

πŸ‡¨πŸ‡³

The Fourth Hospital of Hebei Medical University, Shijiangzhuang, Hebei, China

and more 3 locations
Β© Copyright 2024. All Rights Reserved by MedPath